Clinical trials: Diffuse Cutaneous Scleroderma
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.
- Trial name
- NCT04138485
- Testing
- IgPro10
- Where
- 77 sites in United States, Argentina and 11 more
- Sponsor
- CSL Behring
Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences.
- Trial name
- FASST (NCT02503644)
- Testing
- IVA337
- Where
- 49 sites in Bulgaria, France and 8 more
- Volunteers
- 145 people
- Sponsor
- Inventiva Pharma